Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5
GPCR allosteric modulators target at the allosteric binding pockets of G protein-coupled receptors (GPCRs) with indirect influence on the effects of an orthosteric ligand. Such modulators exhibit significant advantages compared to the corresponding orthosteric ligands, including better chemical tractability or physicochemical properties, improved selectivity, and reduced risk of oversensitization towards their receptors. Metabotropic glutamate receptor 5 (mGlu5), a member of class C GPCRs, is a promising therapeutic target for treating many central nervous system diseases. The crystal structure of mGlu5 in the complex with the negative allosteric modulator mavoglurant was recently reported, providing a fundamental model for designing new allosteric modulators. Computational fragment-based drug discovery represents a powerful scaffold-hopping and lead structure-optimization tool for drug design. In the present work, a set of integrated computational methodologies was first used, such as fragment library generation and retrosynthetic combinatorial analysis procedure (RECAP) for novel compound generation. Then, the compounds generated were assessed by benchmark dataset verification, docking studies, and QSAR model simulation. Subsequently, structurally diverse compounds, with reported or unreported scaffolds, can be observed from top 20 in silico synthesized compounds, which were predicted to be potential mGlu5 modulators. In silico compounds with reported scaffolds may fill SAR holes in known, patented series of mGlu5 modulators. And the generation of compounds without reported tests on mGluR indicates that our approach is doable for exploring and designing novel compounds. Our case study of designing allosteric modulators on mGlu5 demonstrated that the established computational fragment-based approach is a useful methodology for facilitating new compound design in the future.
KEY WORDSallosteric modulator computational fragment-based drug discovery GPCRs metabotropic glutamate receptor 5
Authors would like to acknowledge the funding supports to the Xie laboratory from the NIH NIDA (P30 DA035778A1), NIH (R01 DA025612), and DOD (W81XWH-16-1-0490).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no competing interests.
- 8.Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, Christopoulos A, et al. Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J Med Chem. 2012;55(4):1445–64.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Edwards PD, Albert JS, Sylvester M, Aharony D, Andisik D, Callaghan O, et al. Application of fragment-based lead generation to the discovery of novel, cyclic Amidine β-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency §. J Med Chem. 2007;50(24):5912–25.CrossRefPubMedGoogle Scholar
- 37.Christopher JA, Aves SJ, Bennett KA, Doré AS, Errey JC, Jazayeri A, et al. Fragment and structure-based drug discovery for a class C GPCR: discovery of the mGlu5 negative allosteric modulator HTL14242 (3-chloro-5-[6-(5-fluoropyridin-2-yl) pyrimidin-4-yl] benzonitrile). J Med Chem. 2015;58(16):6653–64.CrossRefPubMedGoogle Scholar
- 38.SYBYL-X 1.3 TI, 1699 South Hanley Rd., St. Louis, MO, 63144, USA. 2010. 2010.Google Scholar
- 40.The PyMOL Molecular graphics system, version 220.127.116.11 Schrodinger, LLC.Google Scholar
- 54.Hogg R, Tanis E. Nonparametric methods. Probability and statistical inference. 4th ed. New York: MacMillan Publishing Co; 1993. p. 589–646.Google Scholar
- 55.Hogg RV, Tanis EA. Solutions Manual, Probability and Statistical Interference: Solutions: Macmillan; 1988.Google Scholar
- 63.Davenport AP, Russell FD. Radioligand binding assays: theory and practice. Current Directions in Radiopharmaceutical Research and Development: Springer; 1996; 169–79.Google Scholar
- 67.Bursavich MG, Gilbert AM, Stock JR. Piperazine metabotropic glutamate receptor 5 (MGLUR5) negative allosteric modulators for anxiety/depression. US Patent; 2009.Google Scholar
- 68.Macdonald G, Tresadern G, Trabanco-Suarez A, Pastor-Fernandez J. Preparation of bicyclic thiazoles as allosteric modulators of mGluR5 receptors. WO Patent; 2011.Google Scholar
- 69.Imogai H, Mutel V, Duvey GA, Cid-Nunez J, Le Poul E, Lutjens R. Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mGluR2-receptors. US Patent; 2005.Google Scholar
- 70.Conn J, Lindsley C, Weaver C, Stauffer S, Williams R, McDonald G, et al. Preparation of O-benzyl nicotinamide analogs as mGluR5 positive allosteric modulators. WO Patent. 2011;Google Scholar
- 71.Imogai HJ, Cid-Nunez JM, Andres-Gil JI, Trabanco-Suarez AA, Santamarina JO, Dautzenberg FM, et al.. 1, 4-Disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors. US Patent; 2014.Google Scholar